Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM.

Gastroenterology. 2012 Sep;143(3):567-75. doi: 10.1053/j.gastro.2012.05.010. Epub 2012 May 21.

2.

Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia.

Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, Lee Y, Friedman R, Asfaha S, Dubeykovskaya Z, Mahmood U, Figueiredo JL, Kitajewski J, Shawber C, Lightdale CJ, Rustgi AK, Wang TC.

Cancer Cell. 2012 Jan 17;21(1):36-51. doi: 10.1016/j.ccr.2011.12.004.

3.

Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients.

Łukaszewicz-Zając M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M.

Dis Esophagus. 2012 Apr;25(3):242-9. doi: 10.1111/j.1442-2050.2011.01242.x. Epub 2011 Sep 2.

PMID:
21895853
4.

Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells.

Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, Cheng E, Wang DH, Spechler SJ, Souza RF.

Am J Physiol Gastrointest Liver Physiol. 2011 Mar;300(3):G454-60. doi: 10.1152/ajpgi.00458.2010. Epub 2010 Dec 9.

5.

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M.

Cancer Cell. 2009 Feb 3;15(2):103-13. doi: 10.1016/j.ccr.2009.01.001. Erratum in: Cancer Cell. 2009 Mar 3;15(3):241.

6.

Barrett's esophagus.

Bird-Lieberman EL, Fitzgerald RC.

Gastroenterol Clin North Am. 2008 Dec;37(4):921-42, x. doi: 10.1016/j.gtc.2008.09.003. Review.

PMID:
19028325
7.

Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression.

Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, Roarty K, Benveniste EN.

Clin Cancer Res. 2008 Aug 1;14(15):4694-704. doi: 10.1158/1078-0432.CCR-08-0618.

8.

The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS.

Jenkins GJ, Cronin J, Alhamdani A, Rawat N, D'Souza F, Thomas T, Eltahir Z, Griffiths AP, Baxter JN.

Mutagenesis. 2008 Sep;23(5):399-405. doi: 10.1093/mutage/gen029. Epub 2008 May 30.

9.

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.

Naugler WE, Karin M.

Trends Mol Med. 2008 Mar;14(3):109-19. doi: 10.1016/j.molmed.2007.12.007. Epub 2008 Feb 7. Review.

PMID:
18261959
10.

Autocrine IL-6 signaling: a key event in tumorigenesis?

Grivennikov S, Karin M.

Cancer Cell. 2008 Jan;13(1):7-9. doi: 10.1016/j.ccr.2007.12.020.

11.

Field defects in progression to gastrointestinal tract cancers.

Bernstein C, Bernstein H, Payne CM, Dvorak K, Garewal H.

Cancer Lett. 2008 Feb 18;260(1-2):1-10. doi: 10.1016/j.canlet.2007.11.027. Epub 2007 Dec 31. Review.

12.

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF.

J Clin Invest. 2007 Dec;117(12):3846-56.

13.

Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus.

Dvorak K, Chavarria M, Payne CM, Ramsey L, Crowley-Weber C, Dvorakova B, Dvorak B, Bernstein H, Holubec H, Sampliner RE, Bernstein C, Prasad A, Green SB, Garewal H.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5305-13.

14.

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M.

Science. 2007 Jul 6;317(5834):121-4. Erratum in: Science. 2009 Dec 4;326(5958):1346.

15.

Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.

Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, Schmidt WE, Tannapfel A.

Gut. 2007 Aug;56(8):1047-53. Epub 2007 Mar 21.

16.

Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus.

Dvorak K, Payne CM, Chavarria M, Ramsey L, Dvorakova B, Bernstein H, Holubec H, Sampliner RE, Guy N, Condon A, Bernstein C, Green SB, Prasad A, Garewal HS.

Gut. 2007 Jun;56(6):763-71. Epub 2006 Dec 4.

17.

Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy.

Abdel-Latif MM, O'Riordan JM, Ravi N, Kelleher D, Reynolds JV.

Dis Esophagus. 2005;18(4):246-52.

PMID:
16128781
18.

Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV.

Am J Gastroenterol. 2005 Jun;100(6):1257-64.

PMID:
15929754
19.

Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues.

Dvorakova K, Payne CM, Ramsey L, Bernstein H, Holubec H, Chavarria M, Bernstein C, Sampliner RE, Riley C, Prasad A, Garewal H.

Am J Gastroenterol. 2005 Feb;100(2):424-31.

PMID:
15667503
20.
Items per page

Supplemental Content

Write to the Help Desk